Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Transforming Health: The Role of the South African Medical Research Council
South African Medical Research is driving meaningful progress in addressing the region’s most pressing health challenges. What are the priorities of the South African Medical Research Council for shaping the future of health? In a recent interview, President and CEO Ntobeko Ntusi explains how the...
Portugal Medicines Reserve: Strengthening Health System Resilience
The Portuguese Government has approved the establishment of a national and regional strategic reserve of medicines and medical devices under the Portugal Transformation, Recovery and Resilience (PTRR) plan, involving an investment of 70 million euros. This measure, announced by Prime Minister LuÃ...
High-Cost Drug Evaluation: Dutch Institute Reduces Assessment Times for Expensive Medications
In High-Cost Drug Evaluation, the Dutch Healthcare Institute Zorginstituut Nederland, announced that the average duration for assessing expensive hospital drug...